4 years ago

Autologous cell therapy for vascular regeneration: the role of proangiogenic cells.

Bagaglia, Pirro, Romani, Kararoudi, Mannarino, Aragona, Fallarino, Bianconi
Autologous cell therapy represents a novel treatment option for vascular regeneration in different disease conditions. Both experimental and clinical studies indicate a therapeutic potential for different proangiogenic cells (PCs), including endothelial progenitor cells (EPCs) in the treatment of peripheral artery disease. A significant improvement of ischemic symptoms has been reported in different trials evaluating PCs for the treatment of critical limb ischemia. However, contrasting results from different meta-analyses question the efficacy of PC-based approaches on long-term outcomes, including amputation and survival. Preclinical studies and clinical trials give support to the safety and feasibility of PC therapy in the treatment of ischemic heart disease and heart failure, while evidence indicating a benefit on the reduction of cardiovascular (CV) events is still uncertain. Clinical studies investigating cell therapy in stroke demonstrated controversial results. Despite accumulating experimental results support a therapeutic role for PCs in diabetic retinopathy, data from randomized clinical trials are lacking. Whether PC therapy may limit vascular damage and premature atherosclerosis and reduce CV risk in inflammatory rheumatic diseases needs to be investigated. Despite a number of potential clinical applications of PCs are emerging, there is evidence that CV risk factors and chronic inflammation may induce PC dysfunction, rising possible limitations for the efficacy of autologous PC therapy. Thus, novel strategies aimed at improving PC viability and angiogenic function are warranted in order to improve the efficacy of cell therapy applications.

Publisher URL: http://doi.org/10.2174/0929867324666171012111603

DOI: 10.2174/0929867324666171012111603

You might also like
Discover & Discuss Important Research

Keeping up-to-date with research can feel impossible, with papers being published faster than you'll ever be able to read them. That's where Researcher comes in: we're simplifying discovery and making important discussions happen. With over 19,000 sources, including peer-reviewed journals, preprints, blogs, universities, podcasts and Live events across 10 research areas, you'll never miss what's important to you. It's like social media, but better. Oh, and we should mention - it's free.

  • Download from Google Play
  • Download from App Store
  • Download from AppInChina

Researcher displays publicly available abstracts and doesn’t host any full article content. If the content is open access, we will direct clicks from the abstracts to the publisher website and display the PDF copy on our platform. Clicks to view the full text will be directed to the publisher website, where only users with subscriptions or access through their institution are able to view the full article.